The ALL treatment has been complicated by extremely severe pancreatitis secondary to asparaginase in the context of germline SPINK1 mutation, requiring treatment adjustment with consolidation with blinatumomab, discontinuation of asparaginase after induction and maintenance without corticosteroids due to diabetes mellitus. The gene discussed is SPINK1; the disease is diabetes mellitus.